News + Font Resize -

Sun Pharma gets US FDA nod to market generic Imitrex injection
Our Bureau, Mumbai | Wednesday, June 22, 2011, 15:55 Hrs  [IST]

Sun Pharmaceutical Industries Ltd. announced that US FDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sumatriptan Succinate Injection, 6 mg (base) / 0.5mL.  This is the first ANDA approval for a Sumatriptan AutoInjector.

This generic Sumatriptan Succinate Injection packaged in a single-dose syringe with AutoInjector is equivalent to Imitrex STATdose System, 6 mg (base) / 0.5 mL of GlaxoSmithKline.  Annual sale for Sumatriptan Succinate Injections in the US is approximately $190 million.

Sumatriptan succinate injection is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes.

Post Your Comment

 

Enquiry Form